 NEW EDITION!
Biosimilars Handbook
The EGA Biosimilars Handbook can be purchased here.
A Italian Version of the EGA Biosimilars Handbook coordinated by ASSOGENERICI can be purchased here.
EXECUTIVE SUMMARY
This second edition of the EGA biosimilars handbook is intended to be a convenient and brief reference source for all those who need to understand biosimilar medicines, this relatively new subclass of biopharmaceutical products. It explains their importance and benefits and provides answers to the many questions raised by this vital new category of medicine. This handbook is particularly targeted towards all those groups that need to understand the background of biosimilar medicines, namely:
- Patients and patient advocacy groups
- Clinicians and prescribers
- Retail and hospital pharmacists
- Those responsible for funding health and healthcare on a regional or national basis
- National Health Technology Assessment (HTA) boards
- National pricing and reimbursement authorities
- Politicians, policy advisers and makers, and healthcare payers
CONTENT OUTLINES
- The Importance of Biosimilar Medicines
- Health Economic Benefits from Biosimilar Medicines
- Nomenclature of Biopharmaceuticals, Including Biosimilar Medicines
- List of European Commission-Approved Biosimilar Medicines
- The Science and Technology of Biosimilar Medicines
- Regulation of Biosimilar Medicines
- Introduction of Biosimilar Medicines into Clinical Practice
- The Future and Evolving Landscape of Biosimilar Medicine
|
